Key statistics
On Wednesday, PharmaEssentia Corp (6446:TAI) closed at 725.00, -7.05% below its 52-week high of 780.00, set on Feb 03, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 733.00 |
|---|---|
| High | 733.00 |
| Low | 710.00 |
| Bid | 724.00 |
| Offer | 725.00 |
| Previous close | 728.00 |
| Average volume | 3.29m |
|---|---|
| Shares outstanding | 379.63m |
| Free float | 302.49m |
| P/E (TTM) | 55.97 |
| Market cap | 275.23bn TWD |
| EPS (TTM) | 12.95 TWD |
| Annual div (ADY) | 0.9898 TWD |
|---|---|
| Annual div yield (ADY) | 0.14% |
| Div ex-date | Aug 11 2025 |
| Div pay-date | Sep 05 2025 |
Data delayed at least 20 minutes, as of Feb 11 2026.
More ▼
Press releases
- PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Support Global Growth of BESREMi®
- PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET)
- FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
- PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
- PharmaEssentia USA Announces Appointment of Jeffrey Williams as Independent Director
- PharmaEssentia Announces Presentation at J.P. Morgan Healthcare Conference and Strategic Priorities for 2026
- PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in The Lancet Haematology
More ▼
